Table 2 Multivariate analysis of overall survival including patients from both Pre-Trastuzumab and Trastuzumab eras
Characteristics | HR (95% CI) | p- value |
|---|---|---|
RPA | ||
1 | 1 [Reference] | |
2 | 1.59 (1.12, 2.27) | 0.009 |
3 | 3.64 (2.52, 5.27) | <0.001 |
ER status | ||
Negative | 1 [Reference] | |
Positive | 0.67 (0.54, 0.84) | 0.001 |
Number of brain lesions | ||
1 | 1 [Reference] | |
2-3 | 1.04 (0.77, 1.41) | 0.80 |
Multiple | 1.36 (1.06, 1.75) | 0.017 |
Craniotomy | ||
No | 1 [Reference] | |
Yes | 0.43 (0.31, 0.58) | <0.001 |
Chemotherapy | ||
No | 1 [Reference] | |
Yes | 0.59 (0.49, 0.73) | <0.001 |
SRS boost | ||
No | 1 [Reference] | |
Yes | 0.40 (0.22, 0.73) | 0.003 |
HER2 (positive vs. negative) | ||
preT-era | 1.02 (0.66, 1.58) | 0.92 |
T-era | 0.49 (0.39, 0.62) | <0.001 |
Hormonal therapy (yes vs. no) | ||
preT-era | 1.09 (0.73, 1.61) | 0.68 |
T-era | 0.62 (0.46, 0.84) | 0.002 |